肺癌十万个为什么欢迎大家加群交流,进群人员请不要发布药品信息,不要轻信任何代购信息,如因此产生的任何问题,本站概不负责!肺癌交流群
官方QQ群:26438631 www.feiai666.com印度易瑞沙

肺癌靶向药物

ID #1348

易瑞沙联合复方丹参滴丸及洛伐他汀抗耐药

有意团购印度易瑞沙 印度特罗凯 印度力比泰 巴西多吉美 印度多吉美 印度索坦(舒尼替尼) 请加入我们的肺癌交流群
官方QQ群1:26438631  群2:5100806(戒烟交流)  或QQ 3 5 7 6 8 7 5 注明 www.feiai666.com

    今天一个群用户给本站提供了一个方法,是在网上找到的,这个方法他也想尝试,因为家人易瑞沙耐药,所以大家也可以尝试看是否管用,此方法与以往方法不太一样,具体参考如下!
    下面介绍一个服用易瑞沙已经3年的肺腺癌病例。
    该病例为晚期肺腺癌(肝转移,骨转移,骨髓转移),经骨髓抽取癌细胞结合CT、彩超于2007年2月确诊。经泰素等化疗6个疗程和骨放射治疗等疗法后,从2007年11月开始服用易瑞沙,服药后一个半月开始起作用(表现为癌性发热消失)。
    8个月后(2008年7月)检查,骨转移灶和骨髓转移灶消失,彩超下肝脏转移灶由全肝脏弥散状态转为三个局限的病灶(最大为1.8*),11个月后(2008年10月),肝脏转移灶消失。原发灶一直维持在小于。表明效果较好。
    至2010年8月检查,肺部病灶扩大至3.5~,肝脏再次出现三个转移灶,大的4CM左右,小的2cm左右。表明对易瑞沙耐药
此时加服复方丹参滴丸(一种治疗心血管病的药物)和洛伐他汀(一种降血脂的药物),试图逆转易瑞沙耐药。并从9月中旬开始作陀螺刀,先作肺部,然后在10月8日开始作肝脏。
    在开始肝脏陀螺刀之前定位病灶时,在CT下检查下发现,肺部病灶已经缩小为左右(此为陀螺刀的效果);肝脏的病灶均小于1cm(此结果明显提示逆转了易瑞沙耐药,因为肝脏还没有开始陀螺刀的伽马射线照射)。
    目前该病人继续口服易瑞沙复方丹参滴丸洛伐他汀治疗。同时每周注射2次超大剂量的维生素C和K3。准备12月中旬作CT和彩超检查评估治疗效果。
    查阅相关资料,有基础研究表明,易瑞沙洛伐他汀联用,可通过甲羟戊酸通路增强易瑞沙的效果,对易瑞沙原发耐药(如肺鳞癌,结肠癌,胶质瘤)或继发耐药的细胞株均有杀伤效果。
    因此,联用易瑞沙洛伐他汀,不失为一种简单的逆转易瑞沙耐药的策略,尽管目前尚无大规模的临床双盲试验的支持。
    计量使用(丹参滴丸的用量是每天10粒(25mg10=250mg),,洛伐他丁的使用量只有一粒(10mg或20mg))

==== 汉译英 ====

Today, a group of users to a site provides a way is found on the web, this method he also wanted to try, because his family Iressa resistance, so we can try to see if effective, this method is not the same with the previous methods specific reference to the following!
    Here is a taking Iressa lung adenocarcinoma 3 years.
    The case for advanced lung adenocarcinoma (liver metastasis, bone metastasis, bone marrow transfer), the marrow is extracted from cells with CT, ultrasound confirmed in February 2007. Taxol and other chemotherapy after 6 cycles and bone radiotherapy treatment, from November 2007 began taking Iressa, began to work after taking a half months (expressed as cancer, fever disappears).
    8 months later (July 2008) examination of bone metastases and bone metastases disappeared, color Doppler ultrasound of liver metastases under the dispersion state to by all the three limitations of hepatic lesions (up to 1.8 *), 11 months after ( October 2008), liver metastases disappeared. Primary focus has been maintained at less than. Show that the effect is good.
    To the August 2010 examination, pulmonary lesions extended to 3.5, the recurrence of three liver metastases, 4CM big about small 2cm or so. Show that the resistance of Iressa.
At this point add services CSDP (a drug treatment of cardiovascular disease) and the lovastatin (a cholesterol-lowering drugs), trying to reverse the drug Iressa. And from mid-September for the gyro knife, first as the lungs, and then start the October 8 for the liver.
    Gyro knife at the beginning of the liver lesions before the positioning, under the inspection under the CT showed pulmonary lesions had shrunk to about (this is the effect of gyro knife); hepatic lesions less than 1cm (This results clearly suggest reversing the Iressa resistance, because liver has not yet begun gyro gamma knife radiation).
    At present, the patient continued oral Iressa, CSDP and lovastatin treatment. Injection of 2 times per week while large doses of vitamins C and K3. In mid-December to prepare for the CT and ultrasonography assessment of treatment effects.
    Access to relevant information, including basic studies have shown that Iressa and combined with lovastatin, mevalonate pathway can be enhanced the effect of Iressa on Iressa primary drug resistance (such as lung cancer, colon cancer, glioma) or secondary resistant cell lines were killing effect.
    Therefore, combined with Iressa and lovastatin, after all, a simple reversal of the strategy Iressa resistance, although there is no large-scale double-blind clinical trial support.

 

Tags: 复方丹参滴丸, 易瑞沙耐药, 洛伐他汀

相关条目: -

更新日期: 2011-02-10 15:11
作者: : mcyclub
修订: 1.1

Digg it! 打印 发送给朋友 输出为PDF文件
请给问答评分:

平均分: 5 来自 5 (1 次评分)

(完全没有价值) 1 2 3 4 5 (非常有价值)

你不能对该内容发表评论